univers coverag
calendar event
medacorp puls call outlook renal cell carcinoma rcc melanoma
opportun io agent tki evolv estimate
medacorp event assess cologuard adopt pcp
medic meet societi laboratori autom screen worldsymposium
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
data rcc earli encourag ph ii combo
bottom line abstract upcom genitourinari cancer symposium asco-gu februari
publish today disclos first clinic data phase combin studi
glutaminas inhibitor plu cabozantinib renal cell carcinoma rcc provid updat
plu everolimu phase studi rcc plu cabozantinib data earli
encourag spoke manag highlight shift focu toward cabozantinib
combin opportun away everolimu combin plan initi
plu cabozantinib cantata phase ii studi believ investor expect
program overal across variou combin indic pursu low current stock level
stock follow initi data plu opdivo phase studi
plu cabozantinib combin opportun rcc repres upsid
estim continu view current valuat attract entri point long-term investor
view op partner program arginas inhibitor promis repres
signific sourc upsid stock continu view well-posit execut
long-term strategi strong manag team financi posit end
cash equival reiter op
earli encourag plu cabozantinib phase rcc data
phase ii cantata studi initi
convers manag highlight shift focu toward cabozantinib combin
anoth cfo transit occur pivot time execut challeng
bottom line remain market perform rate ttoo given fact despit uniqu
technolog detect sepsi shorter period higher sensit vs competitor
market execut challeng continu keep ttoo drive signific adopt
technolog today ttoo announc cfo darlen deptula-hick resign effect
januari complet month compani appoint may prior cfo
left march explan provid resign ttoo indic
enter separ agreement ms hick provid gener releas claim
compani favor incom cfo john spragu replac ms hick go forward
anoth cfo transit could hamper smooth oper growth ttoo pivot time
expect fda approv
expect receiv fda clearanc make pivot time compani
 methodolog dcf discount termin growth rate
bottom line updat model follow top- bottom-lin beat guidanc
consensu driven larg potenti lower extern incom product
sale licens deal well low-to-mid single-digit percentag increas azn alreadi high
sg expens nevertheless continu expect strong imfinzi uptak stage unresect non-
small cell lung cancer nsclc prior follow expect pdufa date base
model updat price target previous remain mp
revenu ep per adr share
 methodolog dcf discount rate termin growth
bottom line beyond posit top-lin progression-fre surviv data link
report top-line beat total sale come estim
street ep quarter line estim penni
consensu confer call focus almost entir result although stock
react neg believ chang made incorpor tumor mutat burden tmb
primari analysi view posit investor provid clear path opdivo nivolumab
yervoy ipilimumab gain approv non-smal cell lung cancer nsclc
repeat statement head tom lynch regard highli statist signific
clinic meaning result well eagerli await secondari overal surviv endpoint tmb
subgroup like gain investor attent week ahead increas peak ww
opdivo yervoy sale forecast base chang model increas
price target reiter op
recent medacorp nsclc survey highlight oncologist expect
combin tmb biomark
recap gear epidiolex launch pipelin progress
bottom line today close gw report result re-affirmed key regulatori
timelin epidiolex rare epilepsi nda file accept
expect regulatori action end respect updat model
quarter -- new price target base epidiolex odds-of-
approv align file accept fda award epidiolex prioriti review ahead
june pdufa management continu focu launch prepar completes/establish
commerci team pipelin gwph anticip epidiolex data tuber sclerosi
complex could form basi snda concurr phase studi
cannabidivarin cbdv partial-onset seizur preview link set read
quarter continu see posit risk/reward cbdv result potenti stock up/
reiter op gwph
epidiolex regulatori review progress gw gear commerci launch
variou chang model led slightli higher price target
gwph end cash cash equival suffici launch
epidiolex fund variou on-going pipelin project
ifr financi revenu mm
strong guidanc surpris earn await full
 methodolog dcf discount rate termin growth
bottom line major surpris earn slight miss top-lin slight
beat bottom-lin driven lower expect tax rate newly-issu guidanc higher
consensu estim total sale non-gaap ep key upcom catalyst
remain full present phase data keytruda alimta pemetrex
mp -base chemotherapi along top-lin result op opdivo
nivolumab yervoy ipilimumab overal surviv os analysi azn
mp mystic imfinzi durvalumab tremelimumab provid
clariti dynam first-lin non-smal cell lung cancer nsclc market
provid guidanc specif time present soon possibl
appropri scientif venu accord management would expect either april
june lower price target due larg
opex assumpt remain mp
like quarter
like quarter
revenu present
receiv fda approv feraheme/label expand
bottom line today issu press-releas announc fda approv snda
regard use intraven iv ferahem ferumoxytol adult non-chron kidney diseas
ckd patient suffer iron defici anemia fda approv come broaden
label indic ferahem wherebi abl posit asset altern
product non-ckd patient suit oral iron therapi even though think
today regulatori decis win enhanc growth top-lin
view catalyst signific long-term needl mover compani stock price
updat model reflect today decis chang previou probabl
result addit top-lin upward adjust pt
reiter mp
revenu present mm non-gaap ep non-gaap ep calcul analyst
succe still wait os management increasingli
bottom line morn report along earn opdivo niovlumab
yervoy ipilimumab arm trial met co-primari endpoint
high degre statist signific progression-fre surviv vs chemotherapi first-
line non-smal cell lung cancer nsclc patient high tumor mutat burden tmb
combin pre-specifi analysi part part portion
trial agre upon fda second co-primari endpoint overal surviv os part
continu final analysi base interim look data monitor committe
clear win view particularli given compani confid posit outcom
os co-primari endpoint understand management also confid potenti
success chemo combo part studi remain complet understand
separ opdivo yervoy combin vs opdivo alon expect color
gx concerta opportun potenti competit
bottom line morn amneal announc launch gener concerta methylphenid
hydrochlorid extended-releas tablet treatment adhd attent deficit hyperact
disord amneal gener ab-rat mean consid therapeut equival
refer list drug concerta recal also gener concerta approv fda
yet launch product would assum condit impax-amn merger stipul
ftc would divestitur one anda expect end launch
gener concerta current assum gener concerta sale
survey direct posit mute hope
lower estim reflect guidanc slower market growth reiter
sale multipl sale estim
super-ior number wide margin efficaci
averag dcf price-to-earnings
limit
outperform market cap price price target methodolog dcf
probability-adjust sale wacc termin growth
vasostrict adrenalin may competit
the-part weight average ev/ebitda multipl
promot suggest clear inventori anticip potenti
hcit distribut preview posit coordin vbc cautiou
medic suppli devic individu co preview cardio large-cap diversifi
tezacaftor/ivacaftor homozyg offer improv toler profil
orkambi potenti approv offer underappreci volum revenu gain
find vertex tez/iva potenti approv low-risk meaning catalyst
vertex sinc combin improv toler profil increas penetr
orkambi exist indic enabl re-treat prior discontinu
management describ tezacaftor/ivacaftor potenti approv greatest near-term driver
top-lin growth us launch
investor could also benefit confirm develop timelin vertex novel
tripl combin therapi begin pivot trial could result
phase dose escal interim safeti data expect earli
recal dose escal on-going variou express solid tumor includ
breast cancer patient score greater nsclc patient express
gastric patient posit post herceptin treatment
risk step given antibody-drug conjug fail due toxic concern
particular thrombocytopenia neutropenia gi toxic ocular advers event
pend determin recommend phase ii dose plan initi
cdtx rezafungin iv phase ii data candidemia system candida
phase ii strive data rezafungin iv expect
cdtx share sold significantli earlier topic program
vulvovagin candidiasi discontinu think perceiv read-through
error continu ascrib odd approv underlin robust pharmacokinet
preclin safeti histor echinocandin data
project probability-weight rezafungin sale
celg ph trial revlimid follicular lymphoma
augment trial approach complet top-lin result releas earli
trial studi cytotoxic-fre combin revlimid rituximab
would attract altern cytotox standard-of-car fl
analysi commerci opportun confer augment suggest success
worth per share
degre upsid limit time like approv adopt
reimburs indic expect generic revlimid
top-lin data expect two ph trial
high level convict derm topic acn program stem clinic valid
robust efficaci data ph iib studi highli power ph program pois
deliv definit result pt medacorp kol check support
strong reimburs access uptak prospect given uniqu on-target
mechan action
hyperhidrosi excess sweat pdufa probability-of-
follow recent success complet futil analysi ph
studi asah patient pivot event edg share set in/around
compani conduct interim analysi see binari event
upsid skew risk/reward
compar vs standard care oral nimodipin asah
succeed interim analysi need better oral nimodipin
base case assum odd success
project probability-weight sale
ionis-httrx phase ib data earli albeit under-follow clinic event
think could offer import proof-of-principl antisens strategi huntington diseas
signific unmet medic need hd repres massiv potenti market
opportun novel disease-modifi strategi
upcom ionis-httrx result import potenti roch
also see meaning read-through op whose antisens hd program also
phase ib month behind
project ionis-httrx probability-adjust sale eu
receiv mid-teen royalti
bold ph i/ii xlmtm crigler-najjar syndrom data
audent expect announc updat phase i/ii aspiro data x-link
myotubular myopathy/xlmtm well preliminari phase i/ii valen data crigler-
najjar syndrom
though small earli natur believ set data
help valid compani gene therapi platform draw investor interest
compani subsequ earlier stage candid like catecholaminerg
polymorph ventricular tachycardia/cpvt pomp diseas
sourc leerink research compani inform factset price prior day
fda adcom joint meet anesthet analges drug product drug
safeti risk manag
fda adcom anesthet analges drug product exparel
propos hous appropri committe deadlin fund feder government
fda adcom neurolog devic panel medic devic evalu clinic
data intracrani aneurysm treatment devic
fda adcom gastrointestin drug panel snda xeljanz ulcer
fda adcom joint meet pediatr endocrinolog metabol drug
achondroplasia
pdufa akao plazomycin complic urinari tract infect bloodstream
pdufa revefanacin lama copd
societi laboratori autom screen
associ access medicin
advanc genom biolog technolog
european crohn coliti organis
advanc technolog treatment diabet
multidisciplinari head neck cancer symposium
american academi dermatolog
bmt tandem meet american societi blood marrow transplant
asbmt center intern blood marrow transplant research cibmtr
societi critic medicin sccm
pittsburgh confer analyt chemistri appli spectroscopi
european congress radiolog ecr
american academi allergi asthma immunolog aaaai /wao
confer retrovirus opportunist infect
intern confer target anti-cancer therapi tat
healthcar inform manag system societi himss
american academi orthopaed surgeon aao
american colleg cardiolog cardiovascular outcom trial
hcit distribut preview posit coordin vbc cautiou
medic suppli devic individu co preview cardio large-cap diversifi
 first apprais tax offer small benefit
 state larg cap biotech sfo steadi goe
 preview tax reform guidanc imp catalyst aet
shade grey
 aet creat new front healthcar outperform larsen
manag cvs-aet neutral ep wcg ci
gupt ana
 aet seek creat new low-cost community-bas model
-- flash /aet may closer deal combin would creat
manag -- flash cvs-aet like dec per share mix
 equiti question gupt ana
 volum start show improv respond aggress
 outperform larsen david
manag aet offens defens consum deal
 aet bring comprehens member
-- flash dementia psychosi btd po surpris basket high risk/
aciu kol lunch support target tau ad interim look advanc
aciu recap pipelin w/ new antibodi select cren
aciu -- flash aciu receiv chf roch phase initi anti-
 growth margin management stabil still lack pipelin catalyst
 aducanumab titrat arm bolster evid treatment effect market
 ctad medacorp call aducanumab abeta hypothesi
 lp hic panel controversi focu ahead data
 roll new ttr model updat spinraza pipelin pt market
 synergi specialti purchas aggress medic
hcit distribut outlook increasingli competit suppli chain
shift vbc
hcit distribut amazon estim matter
hcit distribut wholesal licens may start hub spoke
hcit distribut enter brick mortar space pbm deal could
hcit distribut like take modest size step pharmaci
manag entri drug distribut chain
healthcar distribut suppli chain preview price volum trend
manag -- flash marriag aet jilt altar toward
optum wanna-b
-- flash comment stir lab suppli busi back
 state larg cap biotech sfo steadi goe
chang
 first apprais tax offer small benefit
 vertex alexion top pick
controversi focu ahead drug launch
futur major invest theme backdrop clinic risk
-- flash fourier result chang standard cv patient
 fourier lift statin throne plausibl like
 set new slow-growth outlook get excit pt
biopharma -- flash trulic sustain blow sema must show cv benefit
biopharma -- flash bydureon fail show cv benefit posit novo
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma leerink confer offer first mani face offswil
 model updat reflect goal achiev w/ pipelin success market
mdco anoth step forward cubist vabomer approv pt
novob dc evolut market make pivot year novo
nv -- flash canto suggest role ilari cv uptak reimburs may
nv -- flash surpris win canto hit primari endpoint await
biopharma ada day takeaway healthcar focu canva
biopharma -- flash highlight invokana fda warn puls call modest
impact
biopharma -- flash jardianc win lose wake invokana
medic suppli devic abt/mdt secur approv diabet devic
medic devic cgm libr impact market uncertain still oversold
medic devic ada wrap-up posit meet devic podd/abt/mdt
medic devic leerink leadership seri outset drive shift dialysi self-
novob dc highlight nvo management roundtabl boston market perform
view market
 guidanc show tax reform payoff hard complain
 upgrad op convict top-lin growth accel stori pt
 ar takeaway -- -excit build ahead sinuva launch outperform
 slow growth outlook price power reced upsid limit pt
biopharma price right payer fail get drug class come
biopharma dupix approv price test new paradigm drug access
 volum price pressur continu reduc estim market
esrx aggress price loss competit market pt market
hcit distribut fda take step improv competit distributor near
 dupix price valu money new
tsro zejula price prompt model valuat updat pt lower
 medacorp call gener posit sinuva reimburs prospect
biotechnology/aan recap sma steal show migrain epilepsi pd psych
 american academi neurolog planner
 futur major invest theme backdrop
 neurosci panel takeaway leerink global
 outlook smid biotech theme rnai/antisens id
gwph qtr recap dinner physician bullish uptak ahead
gwph/aan presentation/kol event -- epidiolex profil continu look favorable/
 build solid foundat xlh data could posit ahead
gwph lower pt better data setup still solid
 own dont part wake
-- flash kol call po risk/benefit support major role orphan
management dinner offer perspect pdp launch/strategi
 management dinner offer perspect pdp launch/strategi potenti
-- flash dementia psychosi btd po surpris basket high risk/
 remov toz model safeti setback all-in pt
re-fil inbrija nda parkinson diseas episod believ issu
 kol dinner offer insight emerg drug psych
 recap sma steal show migrain epilepsi pd psych
 upgrad op overhang remov shot base fda/cn
biopharma name shame california latest strategi rein drug
 price sensit analysi show path share upsid pt
healthcar distribut suppli chain preview price volum trend
hcit distribut brand inflat top show deceler y/i
cautiou
hcit distribut volum price appear cautiou suppli chain
ahead earn
 elast demand consist reduc price drive volum growth
pharmaci benefit manag pbmi confer take-away pbm right
side price debat
biopharma -- flash highlight io combin seri puls call front-lin
biopharma highlight io agonist checkpoint puls call updat
biopharma highlight immuno-oncolog kol discuss
biopharma takeaway io remain major area focu
io clinic trial updat crossroad effici
biopharma catalyst tracker busi year ahead neuro oncolog inflamm
biopharma io combo panel takeaway leerink global healthcar
 deep dive highlight oncolog focu strategi nash market perform
 adcetri deep-div highlight upside/downsid pt
 patent fall hurdl humira cut like pipelin loom
achn recap increment advanc patent complement
acr/ patent issuanc enhanc lt valu could add npv
 patent strategi come focu mitig biosimilar risk outpfrm
 doubl extend patent horizon tecfidera
 took money ranminim valu uplift us patent win
biopharma cafc oral argument justic challeng scope ab patent
 patent issuanc reflect execut strategi pt outperform
 recap data ip progress uk/eu mark new year
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg qed ged late stage failur throw ibd bd
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
hcit distribut -- flash minut stori appear one-sid
achn partnership termin push cfd inhibitor main stage pt
 quiet focu remain pot ibs-c partnership catalyst
biopharma viii partnership acquisit biopharma new top list
celg anoth bet car-t probabl probabl sensibl even
 aet bring comprehens member
cori posit updat donepezil pilot studi possibl partnership ye
dplo mid-mkt pbm acquisit complet strateg move market perform
 outperform
 add cscc respons diseas boost /sni
-- flash partner drug advanc phase outperform
 discuss deep dive alks/itci test fda flexibl
alny/ion ttr amyloidosi physician survey
 gwph major takeaway weekend annual
epilepsi meet
 analyst event best idea
outperform
hcit distribut hospit hcit survey highlight shift analyt
healthcar leerink outlook
major highlight medacorp lung cancer survey
focus nsclc
 look diamond rough initi coverag
spec pharma/gener
-- contact leerink repres detail access podcast
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
 pbc survey suggest ocaliva safeti concern manag
 survey payor concern plan upset orphan
 rubraca posit base survey lower est due payer
facil link
hcit distribut demand shift analyt effect use
major medacorp survey lung cancer posit
azn
medic devices-cardiolog tavr survey ew suggest upsid like
reflect share
medic suppli devic survey suggest pickup
 physician survey support nerlynx opp ty breast cancer pt
tsro ovarian cancer survey affirm parp market upgrad op improv risk/
 leadership seri call highlight foundat improv growth ahead
 leerink leadership seri new product growth acceler stori
medic devic leerink leadership seri bigfoot brink disrupt
medic devic leerink leadership seri outset drive shift dialysi self-
medic devices-cardiolog leerink leadership seri target
 leadership call offer insight multipl hot topic controversi
outlook alpha opportun abound healthcar share
